Physician profile
Poornima E Ramadas
NPI 1538696646
$553.55
in general payments reported to CMS, 2019-2025
9 companies · $67.17 in 2025
The $67.17 reported for 2025 was less than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.10 · 2021: $105 · 2022: $18.56 · 2024: $313 · 2025: $67.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $279.54 | 2024-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $102.96 | 2020-2022 | |
| Lilly USA, LLC | $34.13 | 2024 | Zepbound |
| Rhythm Pharmaceuticals, INC. | $29.79 | 2024 | Imcivree |
| Janssen Pharmaceuticals, INC | $27.87 | 2021 | |
| Advanced Respiratory, INC | $23.23 | 2021 | |
| Celgene Corporation | $21.57 | 2025 | Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $19.25 | 2021 | |
| Janssen Biotech, INC. | $15.21 | 2025 | Talvey, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poornima Ramadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.